UiPath Inc. (NYSE:PATH) Q3 2023 Earnings Call Transcript

Brad Sills: Wonderful. Thanks. And then one for you, Ashim, if I may, please, on just the outlook that you provided at the Analyst Day for next year, ARR growth exiting the year at 20%. It’s down quite a bit, I mean, this quarter, you are at 38% constant currency, you are guiding to 20, it looks like 27%, maybe 29% constant currency for Q4, so a pretty big deceleration. Are you assuming a worsening macro in that outlook or if you could just remind us what are you assuming in that number? Thank you.

Ashim Gupta: Yeah. Brad, like, we discussed at Investor Day, the anchor points that we provided for next year assumes the current macro environment that we have all — that we have been talking about, and as well as the FX or the foreign exchange environment that we have also been seeing. We really see this as consistent from forward and our Investor Day until now. We will provide more of an update as we get into next year and report fourth quarter earnings.

Operator: Our next question comes from Mark Murphy with JPMorgan. Please go ahead.

Mark Murphy: Yeah. Thank you and congrats on the great margin progress. So, Ashim, I don’t think you actually spent quite as much time on talking about macro issues tonight. And so I am wondering if it would be logical to think that this period of Q3 and Q4 could represent the trough for the net new ARR. What I mean is, if it’s declining here in this 25% to 40% range and then maybe there would be an opportunity to kind of improve on that as you get further into the repositioning and the repackaging and the go-to-market changes in the first half of next year. Is that — as a general framework, is that a fair way to be thinking about the trending of the business? And then I have a quick follow-up.

Ashim Gupta: Yeah, Mark, it’s very consistent with what we have talked at Investor Day and Analyst Day. We look at the environment as consistent. So we probably have talked less about it just in terms of the environment between Europe, APAC and Americas, we feel relatively the same environment as we talked about just a few months ago. In terms of our commitment to executing on the strategy that we laid out at Investor Day, we are all committed and actually excited about the progress that we are making around segmentation, solutioning, focus, identifying high propensity customers. All of those factors in our mind, we feel are going to yield positive results and that’s what we are executing to. I would remind everybody just we are going to see typical seasonality as we get into next year between first quarter we mentioned in the script, but also first half, second half.

But, overall, we are pleased with the execution of the strategy and we do — we are executing that strategy because we believe it will yield positive results.

Mark Murphy: Okay. Understood. And maybe as a quick follow-up for Rob and Daniel. Could you touch a little on the expanded Microsoft Azure relationship. I believe Microsoft said that UiPath is going to be one of their largest partners that’s built on Microsoft technology, I think, they referred to it that way. What type of opportunity do you see with Microsoft and is that something that’s helping you win business out there incrementally at this point?

Daniel Dines: Thanks for the question. Let me start and then Rob might add more color to it. I feel that we made a good bet on basing on having our technology built on the top of Microsoft Azure cloud that help us drive create cloud offering that resonates with most of our customers. It really helps us to reduce the sales cycle when it comes to the cloud, it reduced the sales cost and it increased time to value to our customers. Microsoft has been really a good partner for us, both on the technology innovation and partnering on the go-to-market side. So we are really looking at a positive development on this front. Rob?

Rob Enslin: I think that’s good. Thanks, Mark

Operator: Thank you. And our next question comes from Raimo Lenschow with Barclays. Please state your question.